CCI-779 in metastatic melanoma: A phase II trial of the California Cancer Consortium.

被引：0
|
作者：
Margolin, KA
Longmate, J
Baratta, T
Synold, T
Weber, J
Gajewski, T
Quirt, I
Christensen, S
Doroshow, JH
机构：
[1] Univ So Calif, Norris Canc Ctr, Los Angeles, CA USA
[2] Univ Chicago, Sch Med, Chicago, IL 60637 USA
[3] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[4] Univ Calif Davis, Sacramento, CA 95817 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7523
引用
收藏
页码：715S / 715S
页数：1
相关论文
共 50 条
  • [11] A phase II study of temsirolimus (CCI-779) in patients with advanced leukemias.
    Yee, KWL
    Garcia-Manero, G
    Thomas, D
    Ani, FRK
    Verstovsek, S
    Andreeff, M
    Dancey, JE
    Giles, FJ
    BLOOD, 2004, 104 (11) : 214B - 214B
  • [12] A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally recurrent endometrial cancer - NCICCTG IND 160.
    Oza, AM
    Elit, L
    Biagi, J
    Gotlieb, W
    Tonkin, KS
    Tsao, M
    Hedley, D
    Hansen, C
    Dancey, J
    Eisenhauer, E
    Seymour, L
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9099S - 9099S
  • [13] Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma
    Witzig, TE
    Geyer, SM
    Ghobrial, I
    Inwards, DJ
    Fonseca, R
    Kurtin, P
    Ansell, SM
    Luyun, R
    Flynn, PJ
    Morton, RF
    Dakhil, SR
    Gross, H
    Kaufmann, SH
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) : 5347 - 5356
  • [14] Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer - NCICIND 160.
    Oza, A. M.
    Elit, L.
    Biagi, J.
    Chapman, W.
    Tsao, M.
    Hedley, D.
    Hansen, C.
    Dancey, J.
    Eisenhauer, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 121S - 121S
  • [15] Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer
    Chan, S
    Scheulen, ME
    Johnston, S
    Mross, K
    Cardoso, F
    Dittrich, C
    Eiermann, W
    Hess, D
    Morant, R
    Semiglazov, V
    Borner, M
    Salzberg, M
    Ostapenko, V
    Illiger, HJ
    Behringer, D
    Bardy-Bouxin, N
    Boni, J
    Kong, S
    Cincotta, M
    Moore, L
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) : 5314 - 5322
  • [16] Phase II Trial of Weekly Bortezomib in Combination with CCI-779 (temsirolimus) in Relapsed or Relapsed/Refractory Multiple Myeloma
    Ghobrial, Irene M.
    Vij, Ravi
    Munshi, Nikhil C.
    Schlossman, Robert L.
    Laubach, Jacob
    Campagnaro, Erica L.
    Leduc, Renee
    Rourke, Meghan
    Chuma, Stacey
    Kunsman, Janet
    Dollard, Akari M.
    Warren, Diane
    Harris, Brianna
    Sam, Amy
    Anderson, Kenneth C.
    Richardson, Paul
    BLOOD, 2009, 114 (22) : 311 - 312
  • [17] Phase I Trial of CCI-779 and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma
    Roccaro, A. M.
    Leduc, R.
    Nelson, M.
    Sam, A.
    Chuma, S.
    Colson, K.
    O'Connor, K.
    Ghobrial, I. M.
    Munshi, N. C.
    Schlossman, R.
    Harris, B.
    Warren, D.
    Dollard, A. M.
    Laubach, J.
    Vij, R.
    Campagnaro, E.
    Birner, A.
    Dixon-Lipscomb, V.
    Anderson, K. C.
    Richardson, P. G.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S86 - S86
  • [18] Phase II safety and activity trial of two dose levels of CCI-779 in women with previously treated locally advanced or metastatic cancer-interim report.
    Chan, S
    Johnston, S
    Scheulen, ME
    Mross, K
    Berger, M
    Kirsch, T
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S132 - S132
  • [19] Final results of a phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma
    Witzig, T
    Geyer, S
    Ghobrial, I
    Inwards, D
    Fonseca, R
    Kurtin, P
    Ansell, S
    Kaufmann, S
    ANNALS OF ONCOLOGY, 2005, 16 : 65 - 65
  • [20] Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: Phase I safety and activity results
    Merchan, J. R.
    Liu, G.
    Fitch, T.
    Picus, J.
    Qin, R.
    Pitot, H. C.
    Maples, W.
    Erlichman, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345